Edition:
United Kingdom

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

145.95EUR
4:35pm BST
Change (% chg)

€0.50 (+0.34%)
Prev Close
€145.45
Open
€145.90
Day's High
€146.00
Day's Low
€141.00
Volume
138,136
Avg. Vol
88,184
52-wk High
€155.95
52-wk Low
€97.24

Chart for

About

Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes... (more)

Overall

Beta: 0.75
Market Cap(Mil.): €9,633.51
Shares Outstanding(Mil.): 83.66
Dividend: 0.85
Yield (%): 0.74

Financials

  IPN.PA Industry Sector
P/E (TTM): 44.34 30.93 32.76
EPS (TTM): 2.60 -- --
ROI: 11.19 15.07 14.61
ROE: 16.34 16.59 16.33

BRIEF-Ipsen Q1 Sales up at 510.3 Million Euros

* IPSEN REPORTS STRONG Q1 2018 SALES GROWTH OF 23.1% AT CONSTANT EXCHANGE RATES

26 Apr 2018

BRIEF-Ipsen Announces EMA Validation Of Filing Of New Application For Additional Indication For Cabometyx®

* ANNOUNCES EMA VALIDATION OF FILING OF A NEW APPLICATION FOR ADDITIONAL INDICATION FOR CABOMETYX®, FOR PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

28 Mar 2018

BRIEF-Ipsen Receives Positive CHMP Opinion For Cabometyx

* IPSEN RECEIVES POSITIVE CHMP OPINION FOR CABOMETYX® (CABOZANTINIB) FOR THE FIRST-LINE TREATMENT OF ADULTS WITH INTERMEDIATE- OR POOR- RISK ADVANCED RENAL CELL CARCINOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

23 Mar 2018

Earnings vs. Estimates